Literature DB >> 29432910

Lactobacillus paracasei 28.4 reduces in vitro hyphae formation of Candida albicans and prevents the filamentation in an experimental model of Caenorhabditis elegans.

Patrícia Pimentel de Barros1, Liliana Scorzoni2, Felipe de Camargo Ribeiro3, Luciana Ruano de Oliveira Fugisaki4, Beth Burgwyn Fuchs5, Eleftherios Mylonakis6, Antonio Olavo Cardoso Jorge7, Juliana Campos Junqueira8, Rodnei Dennis Rossoni9.   

Abstract

The objective of this study was to evaluate the influence of microbe-microbe interactions to identify a strain of Lactobacillus that could reduce the filamentation of Candida albicans ATCC 18804 using in vitro and in vivo models. Thus presenting a probiotic effect against the fungal pathogen. First, we analyzed the ability of 25 clinical isolates of Lactobacillus to reduce filamentation in C. albicans in vitro. We found that L. paracasei isolate 28.4 exhibited the greatest reduction of C. albicans hyphae (p = 0.0109). This reduction was confirmed by scanning electron microscopy analysis. The influence of C. albicans filamentation was found to be contributed through reduced gene expression of filament associated genes (TEC1 and UME6). In an in vivo study, prophylactic provisions with L. paracasei increased the survival of Caenorhabditis elegans worms infected with C. albicans (p = 0.0001) by 29%. Prolonged survival was accompanied by the prevention of cuticle rupture of 27% of the worms by filamentation of C. albicans, a phenotype that is characteristic of C. albicans killing of nematodes, compared to the control group. Lactobacillus paracasei isolate 28.4 reduced the filamentation of C. albicans in vitro by negatively regulating the TEC1 and UME6 genes that are essential for the production of hyphae. Prophylactic provision of Lactobacillus paracasei 28.4 protected C. elegans against candidiasis in vivo. L. paracasei 28.4 has the potential to be employed as an alternative method to control candidiasis.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Candida albicans; Gene expression; Lactobacillus; Pathogenesis; Probiotics; Yeasts

Mesh:

Substances:

Year:  2018        PMID: 29432910     DOI: 10.1016/j.micpath.2018.02.019

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  15 in total

Review 1.  Caenorhabditis elegans as a model animal for investigating fungal pathogenesis.

Authors:  Moses Madende; Jacobus Albertyn; Olihile Sebolai; Carolina H Pohl
Journal:  Med Microbiol Immunol       Date:  2019-09-25       Impact factor: 3.402

2.  Development of Probiotic Formulations for Oral Candidiasis Prevention: Gellan Gum as a Carrier To Deliver Lactobacillus paracasei 28.4.

Authors:  Felipe de Camargo Ribeiro; Juliana Campos Junqueira; Jéssica Diane Dos Santos; Patrícia Pimentel de Barros; Rodnei Dennis Rossoni; Shashank Shukla; Beth Burgwyn Fuchs; Anita Shukla; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

3.  Antimicrobial and Antibiofilm Effect of Inulin-Type Fructans, Used in Synbiotic Combination with Lactobacillus spp. Against Candida albicans.

Authors:  Ricardo García-Gamboa; Miguel Ángel Domínguez-Simi; Misael Sebastián Gradilla-Hernández; Jorge Bravo-Madrigal; Andrés Moya; Marisela González-Avila
Journal:  Plant Foods Hum Nutr       Date:  2022-04-23       Impact factor: 3.921

Review 4.  Fungal-Bacterial Interactions in Health and Disease.

Authors:  Wibke Krüger; Sarah Vielreicher; Mario Kapitan; Ilse D Jacobsen; Maria Joanna Niemiec
Journal:  Pathogens       Date:  2019-05-21

5.  Keeping Candida commensal: how lactobacilli antagonize pathogenicity of Candida albicans in an in vitro gut model.

Authors:  Katja Graf; Antonia Last; Rena Gratz; Stefanie Allert; Susanne Linde; Martin Westermann; Marko Gröger; Alexander S Mosig; Mark S Gresnigt; Bernhard Hube
Journal:  Dis Model Mech       Date:  2019-09-12       Impact factor: 5.758

6.  Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lactobacillus rhamnosus Lcr35® in the Invertebrate Model Caenorhabditis elegans: First Mechanistic Insights.

Authors:  Cyril Poupet; Philippe Veisseire; Muriel Bonnet; Olivier Camarès; Marylise Gachinat; Caroline Dausset; Christophe Chassard; Adrien Nivoliez; Stéphanie Bornes
Journal:  Microorganisms       Date:  2019-12-23

7.  Lactobacillus rhamnosus Lcr35 as an effective treatment for preventing Candida albicans infection in the invertebrate model Caenorhabditis elegans: First mechanistic insights.

Authors:  Cyril Poupet; Taous Saraoui; Philippe Veisseire; Muriel Bonnet; Caroline Dausset; Marylise Gachinat; Olivier Camarès; Christophe Chassard; Adrien Nivoliez; Stéphanie Bornes
Journal:  PLoS One       Date:  2019-11-06       Impact factor: 3.240

Review 8.  The role of Lactobacillus species in the control of Candida via biotrophic interactions.

Authors:  Isabella Zangl; Ildiko-Julia Pap; Christoph Aspöck; Christoph Schüller
Journal:  Microb Cell       Date:  2019-11-25

9.  Probiotic Effects of Lactobacillus paracasei 28.4 to Inhibit Streptococcus mutans in a Gellan-Based Formulation.

Authors:  Janaína Araújo de Alvarenga; Patrícia Pimentel de Barros; Felipe de Camargo Ribeiro; Rodnei Dennis Rossoni; Maíra Terra Garcia; Marisol Dos Santos Velloso; Shashank Shukla; Beth Burgwyn Fuchs; Anita Shukla; Eleftherios Mylonakis; Juliana Campos Junqueira
Journal:  Probiotics Antimicrob Proteins       Date:  2020-09-27       Impact factor: 4.609

Review 10.  Caenorhabditis Elegans and Probiotics Interactions from a Prolongevity Perspective.

Authors:  Marianna Roselli; Emily Schifano; Barbara Guantario; Paola Zinno; Daniela Uccelletti; Chiara Devirgiliis
Journal:  Int J Mol Sci       Date:  2019-10-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.